Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study N. Lerolle, E. Raffoux, G. Socie, S. Touratier, H. Sauvageon, R. Porcher, S. Bretagne, A. Bergeron, E. Azoulay, J.-M. Molina, M. Lafaurie Clinical Microbiology and Infection Volume 20, Issue 11, Pages O952-O959 (November 2014) DOI: 10.1111/1469-0691.12688 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions
FIG. 1 Study flow-chart of patients included in the study. PSC, posaconazole; AML, acute myeloid leukaemia; GVHD, graft-versus-host disease; AHSCT, allogenic haematopoietic stem cell transplantation; IAA, idiopathic aplastic anaemia; MDS, myelodysplastic syndrome; IFD, invasive fungal infection. Clinical Microbiology and Infection 2014 20, O952-O959DOI: (10.1111/1469-0691.12688) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions